share_log

Lyra Therapeutics Shares Are Trading Lower on Continued Weakness After the Company on Monday Announced the ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint. Also, Jefferies Downgraded the Stock From Buy to Hold and Lowered Its Price Target From $10...

Benzinga ·  May 7 08:23

Lyra Therapeutics Shares Are Trading Lower on Continued Weakness After the Company on Monday Announced the ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint. Also, Jefferies Downgraded the Stock From Buy to Hold and Lowered Its Price Target From $10 to $0.5

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment